AMCP 2019 Street Team: Cate Lockhart of Biologics and Biosimilars Collective Intelligence Consortium

Veena Joy, the U.S. autoimmunity lead for medical and scientific affairs at Thermo Fisher Scientific, discusses the latest in autoimmune disease research, and explains why it’s a “good storm,” but not a perfect one.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the "Conversations with Perry and Friends" podcast. In this episode, Cohen speaks with Saar Mahna, J.D., MBA, CEO and founder of Banjo Health, an artificial intelligence company focused on prior authorization.

Farxiga, along with insulin and monitoring for diabetic ketoacidosis, shows promise for kidney and glucose control in youth with Type 1 diabetes.

Perry Cohen, Pharm.D., a longtime member of the Managed Healthcare Executive editorial advisory board, is host of the Conversations with Perry and Friends podcast. In this episode, his guest is Paul Fronstin, Ph.D., director of health benefits research at the Employee Benefit Research Institute.

Step therapy by Medicare Advantage plans was also associated with more injections, although that result fell short of meeting statistical significance standards.

Two presentations discussed the significant care disruptions when there are copay assistance shortages, with patients forgoing effective treatments and turning to lower-cost alternatives with worsening outcomes.